SAN FRANCISCO – Jaguar Health, Inc. (NASDAQ: JAGX) today announced that a preclinical study in mice initiated in Brazil by Magdalena Biosciences,...
MindBio Therapeutics Corp. announced it is nearing the completion of its Phase 2a clinical trial using MB22001 in patients with Major Depressive Disorder....
Awakn Life Sciences Corp. (CBOE: AWKN) (OTCQB: AWKNF) (FSE: 954) (“Awakn”), a clinical-stage biotechnology company developing medication-assisted treatments...
Awakn Life Sciences Corp. (CBOE: AWKN) (OTCQB: AWKNF) (FSE: 954) (“Awakn”), a clinical-stage biotechnology company developing medication-assisted treatments...
–Recently announced positive Phase 1 topline safety, pharmacokinetic (“PK”) and pharmacodynamic (“PD”) data show that intravenous (“IV”)...
Listing fees linked to the recent reverse takeover were significant. The post Safe Supply Posts Q4 Uplisting Costs Ahead of New Game Plan appeared first...
2023— the year that everyone in the psychedelic industry prepared for takeoff. Well, theoretical (but probable) take off. And, just a few weeks before...
-Intravenous (“IV”) CYB004 demonstrated robust and rapid-onset psychedelic effects at lower doses compared to native DMT, suggesting potential as...
Psilocybe fungi, known colloquially as “magic mushrooms,” have held deep significance in Indigenous cultures of Mesoamerica for centuries. They captured...
–Recently announced positive Phase 2 topline data in Major Depressive Disorder (“MDD”) with 79% of patients in remission from depression after two...